Table 1. Results for various drug classes with focus on over-treatment.
| V1: GOLD 1–4_CAT | Number of patients (%) | LABA and/or LAMA | ICS | PDE4 inhibitors |
Oral gluco- corticoids |
|||||||
|
LABA (mono) |
LABA + ICS |
LABA incl. combination drugs (LABA + ICS or LABA) |
LAMA (mono) |
LABA + LAMA incl. combination drugs |
ICS incl. combination drugs (ICS + LABA) |
ICS (mono) |
Triple therapy |
Theophylline | Roflumilast | |||
| A | 247 (10.8%) |
93 (37.7%) |
79 (32.0%) |
170 (68.8%) |
157 (63.6%) |
124 (50.5%) |
114 (46.2%) |
36 (14.6%) |
80 (32.4%) |
14 (5.7%) |
5 (2.0%) |
11 (4.5%) |
| B | 1207 (52.9%) |
458 (38.0%) |
546 (45.2%) |
982 (81.4%) |
857 (71.0%) |
758 (62.8%) |
743 (61.6%) |
208 (17.2%) |
556 (46.1%) |
120 (9.9%) |
86 (7.1%) |
102 (8.5%) |
| C | 41 (1.8%) |
15 (36.6%) |
26 (63.4%) |
39 (95.1%) |
31 (75.6%) |
30 (73.2%) |
31 (75.6%) |
6 (14.6%) |
24 (58.5%) |
2 (4.9%) |
2 (4.9%) |
5 (12.2%) |
| D | 786 (34.5%) |
294 (37.4%) |
449 (57.1%) |
724 (92.1%) |
666 (84.7%) |
630 (80.2%) |
612 (77.9%) |
176 (22.4%) |
525 (66.8%) |
130 (16.5%) |
130 (16.5%) |
169 (21.5%) |
| Total | 2281 | 860 (37.7%) |
1100 (48.2%) |
1915 (84.0%) |
1711 (75.0%) |
1542 (67.6%) |
1500 (65.8%) |
426 (18.7%) |
1185 (52.0%) |
266 (11.7%) |
223 (9.8%) |
287 (12.6%) |
| Guideline-adherent therapy (according to GOLD 2017) | Guideline-adherent according to 2006 NVL (not 2017 GOLD) | Over-treatment | Cannot be classified separately | |||||||||
Absolute frequencies and percentages of the various drug classes in the GOLD groups A-D on the basis of CAT. The percentages for the various medications refer to the number of ?patients in the respective GOLD group, the percentages on the left and lower margins to the analyzable total number of patients (N = 2281). The color codes symbolize that the medication complies with the GOLD criteria (dark blue) or is at least is NVL-compliant (light blue) or represents an over-treatment according to 2017 GOLD recommendations (orange) or could not be evaluated with regard to its appropriateness by itself (gray; see text and for comparison Table 2). The column totals refer to all patients. For a comparison with mMRC see eTable 1 CAT, COPD Assessment Test; ICS, inhaled corticosteroids; LABA, long-acting beta2-agonist; LAMA, long-acting muscarinic antagonist; NVL, German National Disease Management Guideline (Nationale Versorgungsleitlinie); mMRC, modified Medical Research Council; PDE4 inhibitor, inhibitor of phosphodiesterase 4; Triple, LABA + LAMA + ICS